🇺🇸 FDA

Intelligence · Clinical Pipeline

Disc Medicine Pipeline

All ClinicalTrials.gov programs at Disc Medicine — phase, modality, and trial IDs.

Programs
106

Quick answer

Disc Medicine has 106 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. IDP-121 Concentrate for solution for infusion 3 mg/mL

    Disc Medicine

    Chronic lymphocytic leukemia (CLL), Any type of B-cell lymphomas, Multiple myeloma (MM)

    phase 2 small molecule active

    1 trial

  2. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  3. IMCIVREE 10 mg/ml solution for injection

    Disc Medicine

    ROHHAD syndrome

    phase 2 small molecule active

    1 trial

  4. IMFINZI 50 mg/mL concentrate for solution for infusion., Ampligen

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

  5. IPILIMUMAB, MELPHALAN , NIVOLUMAB

    Disc Medicine

    metastasized melonama uveal

    phase 2 small molecule active

    1 trial

  6. Idefirix 11 mg powder for concentrate for solution for infusion

    Disc Medicine

    neuromyelitis optica spectrum disorder, devic disease

    phase 2 small molecule active

    1 trial

  7. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  8. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric peritoneal metastases

    phase 2 small molecule active

    1 trial

  9. Jardiance 10 mg film-coated tablets, BI 690517, Spironolacton Accord 25 mg filmomhulde tabletten, OMNIPAQUE 350 mg I/ml., AMINOHIPPURIC ACID

    Disc Medicine

    Heart failure, cardiovascular disease, chronic kidney disease

    phase 2 small molecule active

    1 trial

  10. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  11. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Vulvar squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  12. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Disc Medicine

    Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

    phase 2 small molecule active

    1 trial

  13. LENALIDOMIDE, PYRIMETHAMINE, TOPIRAMATE

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  14. LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Disc Medicine

    high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer

    phase 2 small molecule active

    1 trial

  15. LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1, LUMC-BOB1-B7-TCR.1

    Disc Medicine

    B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma

    phase 2 small molecule active

    1 trial

  16. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  17. Leflunomide CF 20 mg, filmomhulde tabletten, Hydorxychloroquine 200mg/Placebo, Hydroxychloroquinesulfaat 200 mg Focus, filmomhulde tabletten, Hydroxychloroquinesulfaat CF 200 mg, filmomhulde tabletten, Leflunomide Mylan 10 mg, filmomhulde tabletten, Leflunomide 20mg/Placebo, Leflunomide Mylan 20 mg, filmomhulde tabletten, Plaquenil 200 mg, filmomhulde tabletten

    Disc Medicine

    primary Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  18. Lysergide D-tartrate, Placebo for Lysergide tartrate oral solution

    Disc Medicine

    Chronic cluster headache

    phase 2 small molecule active

    1 trial

  19. Matching placebo for Survodutide, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  20. Mekinist 0.5 mg film-coated tablets

    Disc Medicine

    Neurofibromatosis type 1

    phase 2 small molecule active

    1 trial

  21. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  22. Mesenchymal stem cells, Suspension and solvent for suspension for injection

    Disc Medicine

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  23. Mineral-enriched powder

    Disc Medicine

    Iron Deficiency

    phase 2 other completed

    1 trial

  24. NIVOLUMAB

    Disc Medicine

    Peritoneal Mesothelioma

    phase 2 small molecule active

    1 trial

  25. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  26. NaCl 0,9%, Deferoxamine Noridem 500mg Κόνις για ενέσιμο διάλυμα ή διάλυμα για έγχυση

    Disc Medicine

    Subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  27. Natriumthiosulfat 25%

    Disc Medicine

    Raynaud’s phenomenon

    phase 2 small molecule active

    1 trial

  28. OPDIVO 10 mg/mL concentrate for solution for infusion., JNJ-63723283, Zr89

    Disc Medicine

    Patients with metastatic solid tumours, where clinical data has shown a rationale for ICI therapy.

    phase 2 small molecule active

    1 trial

  29. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  30. PEGINTERFERON ALFA-2A , TIL cells, Zirconium Zr 89 crefmirlimab berdoxam

    Disc Medicine

    Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  31. PYRIMETHAMINE, LENALIDOMIDE, PANOBINOSTAT

    Disc Medicine

    HIV-1

    phase 2 small molecule active

    1 trial

  32. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  33. Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie

    Disc Medicine

    MDS with excess blasts, MDS/AML or AML patients

    phase 2 small molecule active

    1 trial

  34. Psilocybin capsules 15 mg, Psilocybin capsules 25 mg, Psilocybin capsules 1 mg

    Disc Medicine

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    phase 2 small molecule active

    1 trial

  35. RuxoTam; A phase II study to evaluate safety and efficacy of tamoxifen in combination with Ruxolitinib in patients with myelofibrosis

    Disc Medicine

    Myelofibrosis

    phase 2 other active

    1 trial

  36. Rybelsus 7 mg tablets, Kerendia 20 mg film-coated tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Disc Medicine

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  37. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

  38. Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo

    Disc Medicine

    Sjogren's disease

    phase 2 small molecule active

    1 trial

  39. Sitravatinib, Tislelizumab, Sitravatinib

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  40. Skyrizi 600 mg concentrate for solution for infusion

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  41. Skyrizi 600 mg concentrate for solution for infusion, Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  42. Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion., Cinryze 500 IU powder and solvent for solution for injection

    Disc Medicine

    aneurysmal subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  43. Softisan 378, Cannabidiol

    Disc Medicine

    psychological disorders: PTSD; Anxiety disorders

    phase 2 small molecule active

    1 trial

  44. Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)

    Disc Medicine

    Primary aldosteronism

    phase 2 other active

    1 trial

  45. TOPIRAMATE

    Disc Medicine

    human immunodeficiency virus 1 (HIV-1)

    phase 2 small molecule active

    1 trial

  46. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  47. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  48. Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules

    Disc Medicine

    Diffuse Midline Glioma, H3K27-altered

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Disc Medicine have?

106 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.